7^th International Conference on Dementia & Care Practice August 14-16, 2017 Toronto, Canada

Dr. Livio Luongo was born in Naples on 06-September-1979. He received degree in Pharmaceutical Chemistry in 2004. In 2008 terminated the PhD in Pharmacology at the Second University of Naples. During the PhD Dr. Livio Luongo spent half of his PhD in London “Wolfson CARD” King’s College, London, UK, working with Prof. Marzia Malcangio on the mechanism at the basis of neuropathic pain and, in particular, on the involvement of the microglia in the induction and maintenance of symptoms associated with neuropathic pain. In 2012 Dr. Luongo finished the post-doctoral fellowship. In 2013 Dr. Luongo received a national Grant to study the involvement of the peripheral and central immune system in the pathophysiology of neuropathic pain from the National Ministry of Research (1.016.367 €), and he started his own research fellowship. Dr. Luongo is Author of 52 publications and several proceedings.

Neurodegenrative Disorders, Neuropathic Pain Pathophysiology, Pharmocological tools

Dr. Davide Vito Moretti is a consultant neurologist, chief of the clinical neurophysiology service, head chief of the Alzheimer's Disease Rehabilitation Unit at the National Institute of Research and Cure for Mental disorders and Dementia S. John of God, Brescia, Italy, Professor of neurophysiology at UniLudes University in Lugano. He received his medical degree from Catholic University in Rome and completed his residency in neurology and fellowship in movement disorders at University of Trieste, Italy. Moreover, he received the PhD in neurophysiology at La Sapienza University. Dr Moretti is currently involved in research and care of subjects with Alzheimer's disease and movement disorders in the Alzheimer Operative Unit of the S. John of God Institute. Since April 2015, he is responsible of the Research Line in Alzheimer's Disease and Dementia at S. John of God Hospital.

Alzheimer's disease, Parkinson's disease, Dementia and clinical neurophysiology

Dr. Babak Tousi is a geriatrics doctor in Cleveland, Ohio and is affiliated with multiple hospitals in the area, including Cleveland Clinic and Lakewood Hospital. He received his medical degree from Tehran University of Medical Sciences School of Medicine and has been in practice between 11-20 years. He is one of 16 doctors at Cleveland Clinic and one of 2 at Lakewood Hospital who specialize in Geriatrics.He is serving as Medical Director of Cleveland Clinic Center for Brain Health.

Alzheimer's disease

Kurt A Jellinger, born 1931 in Vienna, is Professor of Neurology and Neuropathology at the Medical University of Vienna (Vienna, Austria), was director of the Department of Neurology, Lainz Hospital in Vienna and since 2002, director of the Institute of Clinical Neurobiology (Vienna, Austria). He has been the recipient of numerous international grants and awards, is a member of numerous national and international scientific societies, editor of many international journals of neurology, neuroscience and neuropathology. His publication records exceeds 1,000 in perr-reviewed journals, 170 contributions in scientific book, inclduding several as editor, as well as 1.300 lectures at international meetings. For the last 50 years, his research included many fields of clinical neuropathology, neurochemistry and descriptive neurobiology.

neuropathology, molecular pathology and pathogenesis of movement disorders, neurodegenerative dementias, vascular cognitive disorders, late-life dementia and problems of cell death in CNS aging

Ornit Chiba-Falek is an Associate Professor at the Department of Neurology at Duke University. Her lab has been studying the genetic factors and molecular mechanisms underlying neurodegenerative diseases in aging with a focus on the functional consequences of non-coding variants in dementia and Lewy bodyrelated disorders. She has received her PhD from the Hebrew University in Jerusalem before pursuing her postdoctoral training at the NIH; she was a recipient of the Ellison Medical Foundation New Scholar Program in Aging Award in 2008. She is an Academic Editor for PLoS ONE and serves on the Editorial Boards of JPAand AIMS-Genetics.

Alzheimer Disease, Dementia, Neurodegenrative diseases

Eef Hogervorst did her Ph.D. at Maastricht University in age related cognitive decline and treatment at the Department of Psychiatry and Neuropsychology in 1998. She was subsequently employed at the University of Oxford (Oxford Project to Investigate Memory and Ageing, OPTIMA) as a neuropsychologist and epidemiologist and was awarded several grants and prizes for her research into early diagnoses and risk factors for dementia and cognitive decline. Eef did similar research as a Research Associate Professor at the Donald W. Reynolds Department of Geriatrics (ranked 8th nationally) of the University of Arkansas Medical Sciences and at the University of Cambridge (Department of Psychiatry) as Senior Research Associate, before taking on a Chair in Psychology at Loughborough University which is consistently ranked among the top Universities in the U.K. Eef has set-up collaborations with several large multi-centre observational and treatment studies for age related cognitive decline and dementia (EPIC NORFOLK and MRC CFAS in the U.K. and the H ABC, WHIMS and KEEPS studies in the U.S.A and a large cohort in Indonesia). She studies cross cultural clinical diagnostic accuracy of different types of dementias and has developed and validated a computerized expert system and cognitive test battery for this purpose with Dr Bandelow. Eef is an elected member of the MRC College of Experts for Neuroscience and Mental Health, a member of the European Scientific Referee panel for the European Research Area in Ageing and is often asked to review research proposals (Alzheimer Association, NWO, SPARC etc) and papers in her field (Neurology, JNNP, Arch Neurol, etc). She was invited as a keynote speaker at several conferences (e.g. ICAD). At Oxford Eef was Somerville Junior Research fellow and Blasschko fellow at Linacre College. Eef is an elected young Fellow at the Royal Society of Medicine in London, Editor (Section Head) of the International Faculty 1000, on the editorial board of JAD and has over 100 international peer reviewed publications.

Eef research interests are early diagnoses and modifiable risk and protective factors (e.g. hormones, exercise and nutrition) for dementia and age related cognitive decline; development and validation of cognitive tests and computerized diagnostic systems.

Terry Lichtor completed his MD and PhD degree at the University of Chicago. Dr. Lichtor currently is a practicing Neurosurgeon with research interests including the development of immunotherapeutic strategies for treatment of brain tumors, passive immunotherapy for treatment of Alzheimer’s disease and the development and application of a non-invasive MRI technique for measurement of intracranial pressure and brain compliance.

Alzheimer’s disease,development and application of a non-invasive MRI technique,Immunotherapeutic strategies

Joanna joined Alzheimer’s Family Services Center as Chief Executive Officer in August 2013. With more than 20 years of progressive, professional experience in health care operations and management, Joanna has held executive leadership roles with organizations such as Adventist Health, Diversified Clinical Services, and CRC Health Group. Her background includes direct patient care as well as all aspects of administration in a variety of patient settings. She also has eight years of experience consulting for California Adult Day Programs. Joanna holds a bachelor’s degree in human nutrition, a master’s degree in business administration/finance and is also a registered dietitian.

Alzheimer Care

As a fellowship-trained neurologist subspecializing in movement disorders, Dr. Zhang’s primary clinical and research interests are in Parkinson's disease (PD), tremor, ataxia, and other movement disorders. His particular expertise has led him to focus on the epidemiology of PD, exploring whether nutritional deficiencies in certain populations have an impact on PD. He currently serves as Chair of the Working Group on Genetic & Environmental Risk Factors for PD as part of the largest clinical research consortium in the country, the Parkinson Study Group (PSG). As a member site for PSG, the clinical trial program he leads at UC Davis has participated in many multicenter trials testing new medications for PD, several of which are now used in clinical practice. Dr. Zhang’s other clinical and research interests focus on dystonia and related movement disorders such as facial spasm, limb spasticity, and dystonic tremor, all of which can be treated with neurotoxin injections, most commonly botox. He has participated in registry studies and double-blinded clinical trials for neurotoxin therapeutics, and his services presently offer four different types of neurotoxins to accommodate the patient's needs, symptoms, previous exposure to other toxins, and a variety of other indications. Dr. Zhang also serves as the medical director of the Deep Brain Stimulation (DBS) program at UC Davis and he is very interested in the clinical applications of DBS. Under his direction the DBS program of UCDavis has become a referral center that offers implantation surgery weekly and clinical programming visits daily, serving the greater Sacramento area and northern California.

Neurology, Movement Disorders, Parkinson's Disease

Dr. Silvius is an Associate Professor in the Department of Medicine, Division of Geriatric Medicine, University of Calgary. He has held numerous leadership positions over his career including Division Head, Geriatric Medicine, University of Calgary; Executive Medical Director Southwest Community Portfolio, Calgary Health Region; Medical Director, Pharmacy Services at Alberta Health Services; and most recently a combined role of Provincial Medical Director, Seniors Health and Senior Medical Director, Seniors Health Strategic Clinical Network. External to AHS he has served as Chair of the Expert Committee on Drug Evaluation and Therapeutics, Alberta Health; and is the current Vice-Chair of the Canadian Drug Expert Committee, CADTH. He maintains a clinical practice in geriatrics at Rockyview General Hospital. Other interests include being a co-founder of the Canadian Deprescribing Network (CaDEN), participation in TREC and the DementiaNet, and distance health care delivery. He is the Lead for Medical Assistance in Dying Preparedness, Alberta Health Services.

Dementia Care, Health Care